Reuters Health News 要約
に引き続いて is a 要約 of 現在の health news 簡潔な／要約するs.
South Africa 報告（する）／憶測s first death 予定 to コレラ as 事例／患者s rise to five
One person with no travel history has died 予定 to コレラ in South Africa, the health department said on Thursday, as the number of 確認するd 事例／患者s in the country rose to five. The 開発 comes on the heels of rising 事例／患者s of コレラ in Southern Africa, with Malawi 戦う／戦いing its deadliest 突発／発生 yet, with more than 1,300 deaths.
Moderna's combination 肌 癌 therapy receives FDA's 打開 tag
Moderna Inc said on Wednesday its 実験の personalized mRNA 肌 癌 ワクチン in combination with Merck & Co Inc's 麻薬 Keytruda has received 打開 therapy 任命 from U.S. regulators as an 付加 治療 for high 危険 患者s. 株 of Moderna rise 2.5% to $164 after the market.
分析-Why public health 公式の／役人s are not panicked about bird flu
A new 緊張する of bird flu that 送信する／伝染させるs easily の中で wild birds has 誘発する／引き起こすd an 爆発性の spread into new corners of the globe, 感染させるing and 殺人，大当り a variety of 哺乳動物s 種類 and raising 恐れるs of a pandemic more lethal than COVID-19. But the very changes that have 許すd the ウイルス to 感染させる wild birds so efficiently likely made it harder to 感染させる human 独房s, 主要な 病気 専門家s told Reuters. Their 見解（をとる）s underpin 全世界の health 公式の／役人s' 査定／評価s that the 現在の 突発／発生 of H5N1 提起する／ポーズをとるs low 危険 to people.
上院議員 過密な住居 勧めるs U.S. 特許 office to scrutinize Merck's Keytruda
U.S. 上院議員 Elizabeth 過密な住居 sent the nation's 最高の，を越す 特許 regulator a letter 勧めるing の近くに scrutiny of Merck & Co's requests for new 特許s on its blockbuster 癌 tre atment Keytruda, 説 その上の 成果／努力s to 保護する the 麻薬 could be an 乱用 of the system. "It is not at all （疑いを）晴らす that Merck is doing anything other than 延長するing its monopoly 力／強力にする over the 麻薬," 過密な住居 wrote to Kathi Vidal, director of the 部隊d 明言する／公表するs 特許 and Trademark Office (PTO) in the letter sent on Wednesday and seen by Reuters.
Cambodia 報告（する）／憶測s death of 11-year-old girl from bird flu
Cambodia 報告（する）／憶測d an 11-year-old girl from a 州 east of the 資本／首都 Phnom Penh died after 存在 感染させるd by the H5N1 緊張する of avian influenza, 一般的に known as bird flu. It was the first known human 感染 with the H5N1 緊張する in the Southeast Asian country since 2014, 大臣 of Health Mam Bunheng said in a 声明 on Thursday.
U.S. FDA 認可するs Sanofi's bleeding disorder therapy
U.S. health regulators have 認可するd Sanofi SA's therapy to 扱う／治療する a type of 相続するd bleeding disorder known as hemophilia A, the French drugmaker said on Thursday, and 推定する／予想するs to 開始する，打ち上げる it in the 部隊d 明言する／公表するs in April. With the Food and 麻薬 行政's 是認, Sanofi's 交替／補充 therapy - brand 指名するd Altuviiio - enters a market 支配するd by 競争相手s like Shire, Bayer AG and Novo Nordisk which sell factor 交替／補充 therapies that have been the 基準 治療 for １０年間s.
Nektar 治療力のあるs' autoimmune 病気 麻薬 fails 中央の-行う／開催する／段階 熟考する／考慮する
Nektar 治療力のあるs said on Thursday its 実験の 麻薬, developed in 共同 with Eli Lilly, to 扱う／治療する autoimmune 病気 systemic lupus erythematosus (SLE), had failed a 中央の-行う／開催する／段階 熟考する／考慮する. The 麻薬, rezpeg, did not 会合，会う the 最初の／主要な goal of a 4-point 削減 on SLEDAI-2K 得点する／非難する／２０, a 全世界の 得点する／非難する／２０ing 索引 that 対策 病気 activity in SLE 患者s and 範囲s from 0 to 105.
First Zantac 癌 危険 裁判，公判 in California 延期するd by month s
The first scheduled 裁判，公判 over （人命などを）奪う，主張するs that GSK Plc's heartburn 麻薬 Zantac 原因（となる）d 癌, which had been 始める，決める to begin Monday, has been 延期するd, likely by several months. The 事例／患者, brought by California 居住（者） James Goetz in Alameda 郡 Superior 法廷，裁判所, is now 推定する／予想するd to go to 裁判，公判 in June or July, though no date has yet been 始める，決める, spokespersons for GSK and Goetz's 弁護士／代理人／検事s said on Thursday.
French people's healthy lifespan up by more than 2 years since 2008 - stats 機関
The 量 of time that 65-year-olds in フラン can hope to live without health 問題／発行するs has 増加するd by more than two years since 2008, French 統計（学） 機関 DREES said on Thursday. As 野党s contest a 政府 計画（する） to 増加する the 退職 age by two years to 64 ーするために 妨げる 年金 system 赤字s, DREES said that, in 2021, men 老年の 65 could hope to live another 11.3 years without health 問題／発行するs and women another 12.6 years.
Moderna 予測（する）s COVID sales 拒絶する／低下する as costs rise, 株 落ちる
Moderna Inc on Thursday 予測（する） 拒絶する／低下するing COVID-19 ワクチン sales and rising costs for 2023, raising 関心s the U.S. biotech company could 地位，任命する a loss this year, and its 株 fell 7%. Moderna 予測（する） $6 billion in costs for the year, $1 billion more than the 歳入 it 推定する／予想するs to take in from sales of the COVID 発射.
